Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Spectracef Patent Expiration

Spectracef is a drug owned by Vansen Pharma. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 14, 2016. Details of Spectracef's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5958915 Antibacterial composition for oral administration
Oct, 2016

(8 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Spectracef is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Spectracef's family patents as well as insights into ongoing legal events on those patents.

Spectracef's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Spectracef's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 14, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Spectracef Generics:

There are no approved generic versions for Spectracef as of now.





About Spectracef

Spectracef is a drug owned by Vansen Pharma. Spectracef uses Cefditoren Pivoxil as an active ingredient. Spectracef was launched by Vansen Pharma in 2001.

Approval Date:

Spectracef was approved by FDA for market use on 29 August, 2001.

Active Ingredient:

Spectracef uses Cefditoren Pivoxil as the active ingredient. Check out other Drugs and Companies using Cefditoren Pivoxil ingredient

Dosage:

Spectracef is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
400MG TABLET Discontinued ORAL
200MG TABLET Discontinued ORAL